Medically reviewed by Jay N. Yepuri, MD Biliary colic is abdominal pain that develops due to a blockage in the bile ducts, ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments.

COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed ...

Biliary tract disease describes any disease that affects the biliary tract the gall bladder, bile ducts and accompanying structures. Examples include primary sclerosing cholangitis, secondary ...

HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Biliary Tumor. According to GlobalData, Phase II drugs for Biliary Tumor does not have sufficient historical ...

Primary biliary cirrhosis (PBC) is a chronic, cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, resulting in chronic cholestasis, portal inflammation ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...

Background: The addition of durvalumab or pembrolizumab to gemcitabine and cisplatin (GP) has been approved to statistically improve survival outcomes in patients with advanced biliary tract cancer.

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Doctors assumed he had the seasonal flu and thought he would get better with proper nutrition, hydration and rest. But his ...